Skip to content
10-Q

Quarterly Report

PMV PHARMACEUTICALS, INC. PMVP

0000950170-25-067513

← back to feed
Filed
May 9, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 9, 2025 51.95M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $51.34M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $40.88M
Current Liabilities Q1 2025 · Mar 31, 2025 $9.76M
Current Liabilities Q1 2025 · Dec 31, 2024 $14.37M
Total Liabilities Q1 2025 · Mar 31, 2025 $10.5M
Total Liabilities Q1 2025 · Dec 31, 2024 $15.21M
Current Assets Q1 2025 · Mar 31, 2025 $163.5M
Current Assets Q1 2025 · Dec 31, 2024 $175.66M
Total Assets Q1 2025 · Mar 31, 2025 $170.61M
Total Assets Q1 2025 · Dec 31, 2024 $191.29M
Shares Diluted Q1 2025 · Mar 31, 2024 51.45M sh
Capex Q1 2025 · Mar 31, 2024 $594K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$16.18M
Stockholders Equity Q1 2025 · Mar 31, 2024 $212.68M
Stockholders Equity Q1 2025 · Dec 31, 2023 $225.69M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.30
Eps Basic Q1 2025 · Mar 31, 2024 −$0.30
Sga Expense Q1 2025 · Mar 31, 2024 $5.04M
Rd Expense Q1 2025 · Mar 31, 2024 $13.19M
Net Income Q1 2025 · Mar 31, 2024 −$15.27M
Operating Income Q1 2025 · Mar 31, 2024 −$18.22M